Are lung cancer and COPD clinical trials completely separate?

Yes, they are generally separate. Lung cancer trials test anti-cancer treatments (immunotherapy, targeted therapy, chemotherapy) with tumour response endpoints. COPD trials test symptom management and disease modification (bronchodilators, biologics, pulmonary rehab) with lung function endpoints. However, some screening and prevention trials may include patients at risk for both conditions.

I have both COPD and lung cancer — which trials can I join?

This is common since COPD is a major risk factor for lung cancer. Most lung cancer trials allow patients with comorbid COPD as long as lung function meets minimum thresholds (often FEV1 > 1.0L). COPD trials may exclude patients with active cancer. Your respiratory team can help determine which trials are most appropriate.

Do I need biomarker testing for lung cancer trials?

Yes. Modern lung cancer trials almost always require biomarker testing. EGFR, ALK, ROS1, BRAF, KRAS, PD-L1, and NTRK testing is now standard of care in the UK NHS. Your biomarker profile determines which targeted therapy or immunotherapy trials you're eligible for. COPD trials generally use lung function tests (FEV1, eosinophil count) rather than molecular biomarkers.

Respiratory Comparison Updated 26 May 2026

Lung Cancer vs COPD — Clinical Trial Comparison

🫁

Lung Cancer

NSCLC, SCLC — biomarker-driven treatment

🫁

COPD

Chronic obstructive pulmonary disease

Lung cancer and COPD share a major risk factor — smoking — and frequently co-occur. However, they are fundamentally different diseases requiring different clinical trial approaches. Understanding these differences helps you find the right trial for your condition.

Key Differences at a Glance

Feature	Lung Cancer	COPD
Disease nature	Malignant tumour growth	Chronic inflammatory lung damage
Key diagnostic test	CT scan, biopsy, molecular profiling	Spirometry (FEV1/FVC ratio)
Key biomarkers	EGFR, ALK, KRAS, ROS1, PD-L1, BRAF, MET, RET, NTRK	Eosinophil count, FEV1, Alpha-1 antitrypsin
Treatment goal	Cure (early stage) or prolong survival	Symptom control, reduce exacerbations, slow decline
Common subtypes	Adenocarcinoma, squamous cell, NSCLC, SCLC	Moderate, severe, very severe, Alpha-1 deficiency, chronic bronchitis, emphysema
Smoking link	~85% of cases smoking-related	~80-90% of cases smoking-related

Clinical Trial Availability

Trial Aspect	Lung Cancer	COPD
UK trials actively recruiting	150–250 studies	20–40 studies
Most common trial phase	Phase 2–3	Phase 2–3
Top interventions tested	Immunotherapy, targeted therapy, ADCs, combinations	Triple therapy, biologics, pulmonary rehab, novel bronchodilators
Biomarker-driven trials	Very common (required for most targeted studies)	Emerging (eosinophil-guided therapy)
Adjuvant/neoadjuvant trials	Major category	N/A
Screening/prevention trials	CT screening studies	Smoking cessation, early intervention

Treatment Approaches in Current Trials

Lung Cancer — Hot Trial Areas

Immunotherapy combinations — PD-1/PD-L1 + CTLA-4, IO + chemotherapy, IO + targeted
Targeted therapy — EGFR inhibitors (osimertinib successors), KRAS G12C inhibitors, ALK inhibitors
Antibody-Drug Conjugates — datopotamab deruxtecan, patritumab deruxtecan
Neoadjuvant immunotherapy — CheckMate 816-style pre-surgery treatment
Adjuvant targeted therapy — post-surgery osimertinib, alectinib for ALK+

COPD — Hot Trial Areas

Triple therapy optimisation — ICS/LABA/LAMA combinations and stepping down
Biologics for COPD — dupilumab, itepekimab for eosinophilic COPD
Anti-inflammatory approaches — targeting COPD-specific inflammation pathways
Exacerbation prevention — new strategies to reduce hospital admissions
Pulmonary rehabilitation innovations — digital/home-based programmes
Alpha-1 antitrypsin augmentation — for genetic COPD subtype

💡 Biomarker testing is essential for lung cancer trials

If you have lung cancer, comprehensive biomarker testing (NGS panel) is the most important step for trial eligibility. Your EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, and NTRK status determines which targeted therapy trials you can access. In the UK, NHS Genomic Medicine Service provides this testing — ask your oncologist.

Eligibility Differences

Lung Cancer Trial Criteria

Histologically confirmed diagnosis (NSCLC vs SCLC)
Molecular profiling results required for targeted therapy trials
Stage determines trial category — early-stage (surgery ± adjuvant), locally advanced (chemoradiation), metastatic (systemic therapy)
Prior treatment lines determine sequencing (treatment-naive vs progressed on 1st line)
PD-L1 expression level (TPS score) for immunotherapy trials
Brain metastases status — stable treated brain mets may be allowed

COPD Trial Criteria

Spirometry-confirmed COPD (post-bronchodilator FEV1/FVC < 0.7)
GOLD stage classification (1–4 based on FEV1)
Blood eosinophil count — increasingly used to stratify biologic trials
Exacerbation history (≥2 moderate or ≥1 hospitalised in prior year)
Smoking status — some trials require current smokers, others ex-smokers
Alpha-1 antitrypsin level for AATD-specific trials

🫁 Lung Cancer Trials

Find actively recruiting lung cancer clinical trials across the UK

View Lung Cancer Trials

🫁 COPD Trials

Find actively recruiting COPD clinical trials across the UK

View COPD Trials

Know your biomarkers?

Our Smart Matcher uses biomarker-aware matching to find trials for your specific profile.

Open Smart Matcher